Running title: Pre-clinical efficacy of beta-catenin inhibitor in myeloma.
Introduction
Multiple myeloma (MM) is an incurable neoplastic plasma-cell disorder, accounting for approximately 1% of neoplastic diseases and 13% of haematologic cancers (1) . Despite the improvement in progression-free and overall survival of MM patients after the introduction of high-dose chemotherapy and stem-cell rescue (autologous stem cell transplant (ASCT)) and more effective pharmacotherapies, the available treatment regimens are not curative (2) .
Thus, it is important to continue to identify and validate new therapeutic agents that target alternative pathways, which contribute to the pathogenesis and progression of MM.
The canonical Wnt signalling pathway modulates the balance between stemness and differentiation in several adult stem cell niches, including haemopoiesis within the bone marrow (3) . Furthermore, it is commonly dysregulated in a range of solid tumours including colon, liver and pancreas carcinoma (4) and haematological malignancies including acute myeloid leukaemia (AML) (4, 5) , chronic myeloid leukemia (6) , chronic lymphocytic leukaemia (CLL) (7) , and MM (8) . In the absence of Wnt ligands, cytoplasmic beta-catenin, which is the key player of the Wnt pathway, is constantly degraded by the Axin complex relative LRP5, Dishevelled protein (Dvl) phosphorylates LRP6 leading to the recruitment of the Axin complex to the cell membrane. As such, beta-catenin remains unphosphorylated, accumulates in the cytoplasm and then translocates into the nucleus, where it binds to the TCL/LEF complex initiating transcription of Wnt target genes (9) .
Human myeloma cell lines (HMCL) and primary MM cells have been shown to frequently express active, non-phosphorylated nuclear beta-catenin, whereas in normal B cell subpopulations (naïve, germinal center, and memory B cells) and plasma cells the nonphosphorylated form of beta-catenin is undetectable (8, 10) . Additionally, immunohistochemical study of MM bone marrow biopsies for nuclear expression of betacatenin has revealed strong beta-catenin staining in the malignant plasma cells of 34% of MM patients, where its presence was significantly correlated with more advanced disease stage (11) . Furthermore, Wnt pathway genes (both upstream and downstream of beta-catenin) have been found to be up-regulated in MM primary tumours when compared with normal plasma cells (10) . However, in contrast to other malignancies such as colon carcinoma or hepatocellular carcinoma (HCC) where the up-regulation of the Wnt-canonical pathway is due to mutations involving key components of the pathway, e.g. APC, in MM no such mutations have been found, moreover, further activation of the pathway can be promoted by exposure to activators such as LiCl or Wnt3a, implying the existence of an intact, functional signalling pathway (10, 12) . Consistent with this, evidence suggests that the aberrant activation of the Wnt canonical pathway may be secondary to the expression of Wnt ligands by both MM and bone marrow stromal cells (BMSC) (8, 10) frequently in parallel with coexpression of various Fz receptors and co-receptor LRP6 (12) , and/or the hypermethylation of soluble Wnt inhibitor promoters (11, 13) . Furthermore, recent data indicate that betacatenin can be further stabilized in MM, especially in the nuclear compartment, by the process of SUMOylation (small ubiquitin-like modifier) (14) . SUMOylation is known to be aberrantly activated in MM (15) , and genetic inhibition of the process is able to increase the destruction of β-catenin by the ubiquitin-proteasome system (14) . Overall, the available data confirming the up-regulation of the Wnt canonical pathway in MM, and its potential role in the proliferation, survival and drug resistance of MM cells, make it an attractive therapeutic target.
BC2059 (an anthracene-9,10-dione dioxime compound: 2-((3R,5S)-3,5dimethylpiperdin-1ylsulfonyl)-7-((3S,5R)-3,5-dimethylpiperidin-1-ylsulfonyl) (supplementary figure S1), is a novel Wnt/beta-catenin pathway inhibitor that has been shown to disrupt the binding of betacatenin to Transducin β-like protein 1 (TBL1) and its related protein (TBLR1), facilitating its destruction (16) . TBL1 and TBLR1 were initially identified as members of the co-repressor silencing mediator for retinoid and thyroid hormone receptor (SMRT)-nuclear receptor coreceptor (N-CoR) complex (17) . Upon ligand binding, TBL1-TBLR1 mediate the exchange of the nuclear receptor co-repressors, SMRT-N-CoR, for co-activators. Additionally, TBL1-TBLR1 play a specific role in the recruitment of beta-catenin to the Wnt target-gene promoter. In the absence of Wnt ligands the promoter region of the Wnt target genes is hypoacetylated due to the presence of the repressor complex (TCF, TLE1-HDAC1) whereas upon activation beta-catenin enters the nucleus, binds to TBL1-TBLR1, which preferentially binds to the hypoacetylated histones, thus localising beta-catenin to the region of the Wnt target-gene promoter. Subsequently, beta-catenin interacts with TCF, dissociating TLE1-HDAC1, thus inducing hyperacetylation which leads to the recruitment of co-activators and the initiation of transcription (18) . Interestingly, SUMOylation of TBL1-TBLR1 can further potentiate interaction and transcriptional activation of beta-catenin-TBL1-TBLR1 complex (19) and TBL1, besides acting as a transcriptional co-activator of beta-catenin also protects beta-catenin from degradation (20) . In this study, we show that BC2059, has significant anti- proliferative and pro-apoptotic effects on HMCL and primary MM cells and can mitigate the protective/pro-proliferative effect of stromal cells (SC), Wnt3a or conditioned media (CM) derived from MM patient bone marrow stroma. The drug was confirmed to decrease betacatenin protein levels and the expression of down-stream target genes, furthermore, BC2059 was shown to synergise with low doses of proteasomal inhibitors in killing MM cells and was effective in a murine xenograft model of human MM, thus providing a rational for the further evaluation of the drug in the treatment of MM. 
Materials and methods
copy number of target genes was determined by the comparative threshold cycle method (ΔΔCT) using the Pfaffl method. Data are presented as mean±S.E.M.
Beta-catenin knock down
For beta-catenin knock-down, 2ml of 2x10 5 At day 2 and 3, cells were treated with BC2059 (50nM, 100nM, 150nM) and then harvested at day 4 (72h after transfection). Cell death was monitored by PI staining with FACS, whereas untreated cells were collected for beta-catenin protein level measurement by immunoblotting. Cells were lysed with RIPA lysis buffer, and 70µg of protein was separated by 6% SDS-polyacrylamide gel electrophoresis and blotted onto PVDF as already described.
β-actin (mouse mAb HRP conjugate Cell Signaling Technology) was used as loading control.
In vivo studies
Approval for the murine studies was obtained from the Animal Ethics Committee of the 
ubiquitin and IRES promoter respectively). At day 21 a limited course of treatment was commenced after confirmation of established measurable disease by bioluminescence.
Control mice (n=4) received 17% Solutol® HS 15 (Sigma-Aldrich), whereas treated mice received 5mg/kg (n=4) or 10mg/kg BC2059 (n=5) twice a week i.v. for 3 consecutive weeks (6 doses in total). Tumour burden was monitored on a weekly basis by in vivo imaging, from the 2 nd week of the experiment (day 18) until the first mice reached scientific end-points.
Briefly, mice were anaesthetised, injected intraperitoneally (i.p.) with 125mg/kg luciferin, and imaged with the Lumina III XR system (Perkin Elmer). Acquisition and analysis was performed with the Living Image system. Peripheral blood counts were evaluated sequentially during the course of the experiment (Hemavet®, Drew Scientific, Inc.). Upon reaching scientific end-points (e.g. hind limp paralysis, >20% weight loss) mice were humanely euthanised and tissues (skin and colon) collected. Tissues were formalin-fixed and embedded in paraffin, sectioned, and stained with H&E and beta-catenin antibody. Images were taken with an Olympus BX51 microscope.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA, USA).
Results

Targeting the dysregulated Wnt/canonical pathway by BC2059 induces apoptosis in HMCL
We first evaluated beta-catenin expression pattern in a panel of 12 genetically heterogeneous HMCL and confirmed the presence of nuclear beta catenin in all cases ( Figure 1A) , found to secrete Wnt ligands that likely contribute to the observed dysregulation of the Wnt/beta-catenin pathway in MM (5). We therefore evaluated the pro-necrotic effect of BC2059 on NCI H929 and KMS18 cultured with HS5. Baseline cell death of HMCL was similar in both conditions (alone or co-culture) for both cell lines tested (NCI H929 alone:13%±2.68, coculture:16%±1.34, KMS18 alone: 11.13±0.4, co-culture: 11.7%±1.1). At low doses of the drug stromal cells significantly protected HMCL from cytotoxicity, whereas addition of BC2059 at doses equal to IC 80 mitigated the pro-survival effect of the stromal cells, with >50% cell death achieved in both cases (Figure 2A ). Cell death of the stromal cells by the drug did not exceed 14.8% at the highest doses (500nM) both when cultured alone and in the co-culture system ( Figure 2B ). BC2059's lack of cytotoxicity on HS5 stromal cells could be attributed to the undetectable levels of beta-catenin protein in these cells (figure 2C), when compared with a HMCL (KMS18). Similarly, the growth advantage of NCI H929 when cultured with CM derived from MM-patients (CM1 and CM2) ( Figure 2D ) or rhWnt3a ( Figure 2E ) was inhibited by BC2059 in a dose dependent fashion.
Interestingly, exposure to rhWnt5a ligand, a known activator of the non-canonical pathway, under the same conditions had no proliferative effect on NCI H929 ( Figure 2F ).
BC2059 induces apoptosis of primary MM cells and synergises with bortezomib.
To assess the potential of BC2059 for future combination treatment approaches HMCL were treated with BC2059 and the proteasome inhibitor bortezomib at a range of doses and the presence of synergy calculated using Calcusyn software (CI <1 defines synergism). For 6 of 7 HMCL, the combination was synergistic or additive with doses ranging from IC 20 
BC2059 demonstrates anti-MM activity in vivo and has minimal toxicities.
We then evaluated the in vivo effect of BC2059 utilising a xenograft murine model of systemic human myelomatosis. NSG mice were transplanted (i.v.) with U266 HMCL stably expressing GFP and lusiferase2. After 3 weeks, when disease was established in all cases, the mice were treated with vehicle alone, 5mg/kg BC2059 or 10 mg/kg BC2059 twice weekly for three consecutive weeks (d21-d39, 6 doses in total). Tumour burden was monitored on a weekly basis with in vivo bioluminescence imaging after i. 
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documented. Upon the development of signs of disease the mice were euthanised and tissues (skin and colon) collected for histopathologic studies. The mice treated with 5mg/kg showed a significant delay of tumour growth compared to vehicle only after the termination of treatment (p=0.0085 and p=0.0078 in day 46 and day 53 respectively), whereas mice treated with 10mg/kg of BC2059 demonstrated a significantly slower rate of tumour growth since the beginning of treatment (with the exception of day 39) (p=0.014, p= 0.016, p=0.0038 and p=0.0075 in day 25, 32, 46, 53 respectively) ( Figure 6A ). Moreover, mice treated with the higher dose of BC2059 (10mg/kg) even with a total of only 6 doses of BC2059 demonstrated superior survival (p=0.024) when compared to the vehicle cohort ( Figure 6B ).
Importantly, treatment with BC2059 did not result in either weight loss or peripheral blood cytopenias ( Figure 6C ) when compared to vehicle-treated mice.
Finally, in view of the importance of the Wnt/beta-catenin pathway on the homeostasis of adult skin and intestine we performed immunohistochemical studies of the dorsal skin and colon harvested at the time of euthanasia. Interestingly, although we did not notice any macroscopic skin changes, the biopsies from treated mice showed dose dependent stalling of the hair cycle process after involution with variable recycling of hair occurring. At 5mg/kg the process was patchy, whereas at 10mg/kg the process was more diffuse with concurrent fibrosis and loss of the dermal adipocyte tissue ( Figure 6D ), consistent with an on-target cutaneous effect of BC2059 due to down-regulation of beta-catenin expression in hair follicle cells ( Figure 6E ). In contrast, no significant histological changes were seen in the gastrointestinal tract of the drug treated mice (supplementary Figure 3) . 
Discussion
The aetiology of a range of diverse malignancies, including haematologic neoplasms, may be attributable, at least in part, to Wnt canonical pathway dysregulation (4, (22) (23) (24) . Furthermore, while beta-catenin expression is normally lost in healthy differentiated B-lineage plasma cells, its expression, and transcriptional activity in conjunction with TCF is maintained through a yet unknown mechanism in some MM cells (8, 10) . The presence of high levels of nuclear beta-catenin (active form) in all of the HMCL that we tested is consistent with the latter and implies that up-regulation of the Wnt pathway may be a common, albeit probably late (11) , event in the progression of MM irrespective of the underlying genetic make-up of the disease. We demonstrated, in accordance with previous published data (8, 12) , that the Wnt canonical pathway in MM can be further stimulated with the addition of Wnt3a ( Figure   2E ), promoting the proliferation of the MM cells and is consistent with an intact Wnt pathway. Furthermore, our finding that enhanced activation of the Wnt pathway confers further growth and survival advantage to MM is in accordance with previously published data (8, 10) , and provides a strong basis to evaluate blockade of the Wnt pathway as a potential therapeutic modality for the treatment of MM.
We demonstrated that BC2059 exposure reduced nuclear beta-catenin protein levels in a dose and time dependent manner and specifically impaired beta-catenin/TCF transcriptional activity without any evidence of interference, based on the reduction in the overall cellular level of beta-catenin, of beta-catenin binding to its destruction complex. According to previously published data (16) , the drug interferes with the interaction of beta-catenin with TBL1-TBLR1, which are uniformly expressed in HMCL (supplementary Figure S4 ) and which have a dual role of facilitating the transcriptional activity of the former (18) , as well as protecting it from Siah-1 mediated degradation both in the nucleus and cytoplasm (20) . Thus, BC2059 not only decreases the transcription of beta-catenin target genes, but also decreases Furthermore, partial decrease of the protein by siRNA knock-down was able to decrease the cytotoxic effect of the drug ( Figure 5C ). Due to the complex and context specific mechanisms that govern the Wnt/beta-catenin pathway and the possible compensatory routes for persistent β-catenin/TCF4-regulated transcription, primarily lowering β-catenin levels is not, as might be expected, enough to fully abrogate the effect of the drug. This is further supported by the Wnt ligands, we tested the effect of BC2059 in the presence of MM patient derived stromal cell CM and rhWnt3a. In both instances BC2059 was able to abrogate, in a dose dependent manner, the proliferative stimulus provided to the MM cells. In contrast, exposure to rhWt5a provided no proliferative benefit to the HMCL thus demonstrating the pathway specificity (canonical versus non-canonical) of Wnt dysregulation in promoting MM growth and survival. Collectively, considering the complexity and tissue-specificity of the Wnt-canonical pathway, these results demonstrate specificity for BC2059, albeit minor off-target effects cannot be totally excluded.
Beta-catenin up-regulation has been correlated with bortezomib resistance providing a clear rationale for the combination of BC2059 with bortezomib to enhance the anti-MM effect with the least possible toxicity (26) . Accordingly, the addition of bortezomib to BC2059 proved to be synergistic against the HMCL and the primary MM cells tested, moreover, in one case, absolute in vivo resistance to bortezomib confirmed in the clinical setting, was partly overcome ex vivo by the addition of BC2059. Taken together these results suggest that bortezomib resistance, that may in part be attributable to beta-catenin up-regulation, may be overcome by the addition of BC2059. termination of imaging when compared to control animals (figure 6B). One of the biggest challenges in the development of Wnt/beta-catenin pathway inhibitors is to diminish the possible on-target effects on other Wnt-dependent healthy tissues. In this context we evaluated treated animals for clinical and histological evidence of the on-target effects of BC2059. MM-bearing mice objectively tolerated the treatment well, with no major hair-loss or differences in body weight between the cohorts, the latter consistent with functional integrity of the gastrointestinal track. Furthermore, colon biopsies did not reveal any major changes attributable to Wnt/beta-catenin inhibition. In contrast, skin biopsies demonstrated dose dependent dysregulation of normal hair cycling with a concomitant reduction in adipose tissue (hypodermis) and increased thickness of the dermis. It has been already shown (27) that inhibition of the epidermal Wnt/beta-catenin signalling reduces adipocyte differentiation in the adult mouse dermis. This negatively affects the synchronised adipocyte differentiation and hair growth cycle, which follow an oscillating pattern throughout adult life. Our findings 
